The day in pharma, read in minutes.
NewsData Integrity, Not Scale, Is India's Real Competitive Advantage - Chakravarthi AVPS on India's Pharma Leadership at GPACTS 2026
At GPACTS 2026, Chakravarthi AVPS declared data integrity, not scale, as India's pharma competitive advantage amid FDA, EMA scrutiny and AI-driven manufacturing.
FDA Issues Emergency Guidance After Neonatal PN Supply Shutdowns
Novartis Pelacarsen Fails Phase III Lp(a) Trial
AstraZeneca Wins FDA Approval for Camizestrant in Breast Cancer
FDA Flags ZUBB Supplement for Hidden Sildenafil
Latest news
11 storiesTarsus Acquires Alkeus, Adds Phase 3 Stargardt Drug
Tarsus Pharmaceuticals closes Alkeus acquisition, adding FDA Breakthrough-designated ALK-001 for Stargardt disease to its Phase 3 pipeline.
Teva Gains Investment-Grade Status from All Three Major Rating Agencies After S&P Upgrade
S&P upgrades Teva to BBB-, completing investment-grade ratings from all three major agencies and signalling durable generics stabilisation.
FDA CBER Consolidates Biologics Regulatory Resource Hub for BLA and Compliance Teams
CBER's consolidated resource hub covers BLA submissions, 21 CFR 600–680 compliance, and postmarketing obligations for biologics manufacturers.
Peptides & Complex Generics Symposium 2026 Returns to Mumbai
**Panel Discussion | The Rapid Rise of GLP-1 Drugs, Weight Loss, Wellness & Beyond** As part of the **inaugural edition of Peptides & Complex Generics (PCG)**, this insightful panel brought together leading voices from across the pharmaceutical and healthcare ecosystem to discuss the rapidly evolving landscape of GLP-1 drugs and their impact on weight loss, wellness and beyond. Featuring, from left to right: **Mr. Vikas Dandekar**, Editor (Pharma and Healthcare), The Economic Times **Mr. Vikrant Shrotriya**, Corporate Vice President and Managing Director, Novo Nordisk **Mr. Winselow Tucker**, President, Eli Lilly & Co. (India) Pvt. Ltd. **Mr. Siddharth Mittal**, MD & CEO, Syngene International; Ex-CEO & MD, Biocon Ltd. **Dr. Subramanian Narayanaswamy**, Head of Delivery, Parenteral Injectables – IPDO, Dr. Reddy’s Laboratories **Mr. Jatin Vimal**, Director, Levim Lifetech Pvt. Ltd. A powerful discussion reflecting the growing significance of GLP-1 therapies and the opportunities and challenges shaping the future of this rapidly advancing space. #PCG2026 #Peptides #GLP1 #Pharma #Healthcare
20260904181404.webp&w=1920&q=75&dpl=dpl_CE3VACNCZ5AoAf3CQ76nP9jikDry)
AstraZeneca, HUTCHMED Win Phase III NSCLC Trial
SANOVO Phase III data back Tagrisso-Orpathys as first-line NSCLC therapy in China, triggering label expansion and manufacturing scale-up decisions.
Weave Bio and Takeda Deploy AI Regulatory Platform Across 14 Drug Programs
Weave Bio's AI regulatory platform is live across 14 Takeda drug programs, setting a cross-portfolio benchmark for submission workflow automation.
AbbVie Achieves 60% Progression Risk Reduction for Etentamig in Phase 3 Multiple Myeloma Trial
AbbVie's etentamig cut progression risk by 60% across dual primary endpoints in Phase 3, signaling a likely BLA filing and bispecific scale-up challenge.
Cipla Signs Qilu Deal to Launch Pembrolizumab Biosimilar in U.S.
Cipla partners Qilu Pharmaceutical to commercialise a pembrolizumab biosimilar in the US, targeting Merck's Keytruda as patent exclusivity narrows.
EMA Resolves Visudyne Shortage After Registering New EU Manufacturing Sites for Verteporfin
EMA finalises new EU manufacturing sites for Visudyne, targeting full supply restoration by 2027 after years of controlled distribution.
EMA PRAC Launches Safety Review of Injectable Iron Medicines Over Hypophosphataemia and Bone Risk
EMA's PRAC has opened a formal safety referral on injectable iron medicines, citing inadequate risk controls for hypophosphataemia and bone disorders.
CMS's Dermavon Gains NMPA Approval for Lumirix in Pediatric Atopic Dermatitis
CMS's Dermavon secures NMPA priority-review approval for topical JAK inhibitor Lumirix in atopic dermatitis, including children from age two.
Worth your time this week
Agilent Launches ICP-MS, GC Systems and Digital Lab Platform
Cohance Lifesciences Secures $18M Stake in NJ & Aruka Bio
RPG Life Sciences Acquires Raghava Life Sciences API Business
